Dabur shares slide as USFDA observations trigger investor concerns

MUMBAI: A bitter pill for investors arrived before breakfast. Dabur India found itself under the regulatory spotlight and market pressure after disclosing that it is engaging with the US Food and Drug Administration (USFDA) over observations made at its manufacturing facility in Silvassa. The development rattled investors, sending the FMCG major’s shares down more than 4 per cent during Monday’s trading session.

The company moved quickly to contain concerns, stressing that the observations relate to only a small section of its facility in Dadra and Nagar Haveli, a unit that contributes an insignificant share of overall revenue. Dabur also clarified that the plant remains operational and that there is no impact on its business operations or financial performance.

The disclosure follows a Form 483 inspection report issued by the USFDA after an audit of the facility earlier this year. The report flagged several concerns spanning manufacturing practices, maintenance procedures and data integrity systems.

Among the observations were alleged lapses in equipment cleaning and sanitation, questions around microbiological testing processes, and concerns over quality control systems. Inspectors also reportedly identified conditions that could raise contamination risks, including bird droppings near packaging storage areas and unidentified black residue on parts of warehouse ceilings. The report further alleged that certain manufacturing records may not have been maintained accurately.

Dabur said it has already submitted a comprehensive corrective and preventive action plan to the regulator and is providing regular updates on remediation efforts. The company reiterated that it remains committed to maintaining stringent quality standards and ensuring its manufacturing systems continue to operate without compromise.

While the observations do not automatically lead to penalties or restrictions, Form 483 reports are closely watched by investors because unresolved issues can escalate into warning letters or more severe regulatory action if corrective measures fail to satisfy authorities.

The episode arrives at a delicate time for the company. Over the years, Dabur has expanded beyond its traditional Ayurvedic roots into a broader portfolio of consumer healthcare products, nutraceuticals and international markets. The United States remains an important export destination for several of its over-the-counter healthcare products, including oral care, pain relief and antifungal treatments.

More broadly, the development underscores the heightened regulatory scrutiny facing Indian healthcare and consumer goods manufacturers serving global markets. As companies chase international growth, compliance standards are becoming just as important as market share.

For now, Dabur insists it is addressing the concerns and that business continues as usual. Investors, however, appear to be taking a wait-and-watch approach, a reminder that in global markets, quality control is no longer just a factory-floor issue, it’s a boardroom and stock-market concern too.